7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
5
0
0
Last 30D
0
0
1
0
0
1M Ago
0
0
0
0
0
2M Ago
0
1
1
0
0
3M Ago
0
1
3
0
0
Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $25.29, accompanied by a high estimate of $42.00 and a low estimate of $17.00. This current average has decreased by 3.36% from the previous average price target of $26.17.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive NovoCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Emily Bodnar
HC Wainwright & Co.
Maintains
Neutral
$22.00
$22.00
Emily Bodnar
HC Wainwright & Co.
Lowers
Neutral
$22.00
$24.00
Jason Bednar
Piper Sandler
Raises
Overweight
$28.00
$25.00
Larry Biegelsen
Wells Fargo
Lowers
Overweight
$42.00
$49.00
Emily Bodnar
HC Wainwright & Co.
Raises
Neutral
$24.00
$22.00
Jessica Fye
JP Morgan
Raises
Neutral
$17.00
$15.00
Emily Bodnar
HC Wainwright & Co.
Maintains
Neutral
$22.00
-
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, ...Full story available on Benzinga.com
Benzinga
